The C-terminal module IV of connective tissue growth factor, through EGFR/Nox1 signaling, activates the NF-κB pathway and proinflammatory factors in vascular smooth muscle cells

Antioxidants and Redox Signaling

Volumn 22, Issue 1, 2015, Pages 29-47

  Rodrigues Diez, Raúl R ^a   Garcia Redondo, Ana Belen ^a   Orejudo, Macarena ^a   Rodrigues Diez, Raquel ^a   Briones, Ana Maria ^a   Bosch Panadero, Enrique ^a   Kery, Gyorgy ^b,c   Pato, Janos ^c   Ortiz, Alberto ^a,d   Salaices, Mercedes ^a   Egido, Jesus ^a,d,e   Ruiz Ortega, Marta ^a  

^a UNIVERSIDAD AUTÓNOMA DE MADRID   (Spain)

^b SEMMELWEIS UNIVERSITY   (Hungary)

^c Vichem Chemie Ltd   (Hungary)

^d Section of Nephrology   (Spain)

^e INSTITUTO DE SALUD CARLOS III   (Spain)

Author keywords

[No Author keywords available]

Indexed keywords

CONNECTIVE TISSUE GROWTH FACTOR; ENDOTHELIAL NITRIC OXIDE SYNTHASE; EPIDERMAL GROWTH FACTOR RECEPTOR; ERLOTINIB; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; INDUCIBLE NITRIC OXIDE SYNTHASE; NEURONAL NITRIC OXIDE SYNTHASE; OXYGEN; PARTHENOLIDE; PHENYLEPHRINE; REACTIVE OXYGEN METABOLITE; REDUCED NICOTINAMIDE ADENINE DINUCLEOTIDE PHOSPHATE OXIDASE 1; SUPEROXIDE; CTGF PROTEIN, MOUSE; OXIDOREDUCTASE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA; AORTA CONSTRICTION; ARTERY DILATATION; ARTICLE; BLOOD VESSEL REACTIVITY; CARBOXY TERMINAL SEQUENCE; CONTROLLED STUDY; ENDOTHELIAL DYSFUNCTION; ENZYME ACTIVATION; EX VIVO STUDY; GENE OVEREXPRESSION; GENE SILENCING; IN VIVO STUDY; MALE; MOUSE; NITROSYLATION; NONHUMAN; OXIDATION REDUCTION REACTION; OXIDATIVE STRESS; SIGNAL TRANSDUCTION; SMOOTH MUSCLE FIBER; TRANSCRIPTION INITIATION; VASCULAR SMOOTH MUSCLE; ANIMAL; CONFOCAL MICROSCOPY; CYTOLOGY; IMMUNOHISTOCHEMISTRY; METABOLISM; SMOOTH MUSCLE CELL;

MURINAE; MUS;

ANIMALS; CONNECTIVE TISSUE GROWTH FACTOR; IMMUNOHISTOCHEMISTRY; MALE; MICE; MICROSCOPY, CONFOCAL; MUSCLE, SMOOTH, VASCULAR; MYOCYTES, SMOOTH MUSCLE; NADH, NADPH OXIDOREDUCTASES; NF-KAPPA B; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84919361015     PISSN: 15230864     EISSN: 15577716     Source Type: Journal    
DOI: 10.1089/ars.2013.5500     Document Type: Article

References (72)

1. Ahmed MS, Gravning J, Martinov VN, von Lueder TG, Edvardsen T, Czibik G, Moe IT, Vinge LE, Øie E, Valen G, and Attramadal H. Mechanisms of novel cardioprotective functions of CCN2/CTGF in myocardial ischemiareperfusion injury. Am J Physiol Heart Circ Physiol 300: H1291-H1302, 2011.
2. Al Ghouleh I, Khoo NK, Knaus UG, Griendling KK, Touyz RM, Thannickal VJ, Barchowsky A, Nauseef WM, Kelley EE, Bauer PM, Darley-Usmar V, Shiva S, Cifuentes-Pagano E, Freeman BA, Gladwin MT, and Pagano PJ. Oxidases and peroxidases in cardiovascular and lung disease: new concepts in reactive oxygen species signaling. Free Radic Biol Med 51: 1271-1288, 2011.
3. Branchetti E, Poggio P, Sainger R, Shang E, Grau JB, Jackson BM, Lai EK, Parmacek MS, Gorman RC, Gorman JH, Bavaria JE, and Ferrari G. Oxidative stress modulates vascular smooth muscle cell phenotype via CTGF in thoracic aortic aneurysm. Cardiovasc Res 100: 316-324, 2013.
4. Briones AM, Rodríguez-Criado N, Hernanz R, García-Redondo AB, Rodrigues-Díez RR, Alonso MJ, Egido J, Ruiz-Ortega M, and Salaices M. Atorvastatin prevents angiotensin II-induced vascular remodeling and oxidative stress. Hypertension 54: 142-149, 2009.
5. Briones AM and Touyz RM. Oxidative stress and hypertension: current concepts. Curr Hypertens Rep 12: 135-142, 2010.
6. Chan EC, Peshavariya HM, Liu GS, Jiang F, Lim SY, and Dusting GJ. Nox4 modulates collagen production stimulated by transforming growth factor b1 in vivo and in vitro. Biochem Biophys Res Commun 430: 918-925, 2013.
7. Chen CC, Young JL, Monzon RI, Chen N, Todorović V, and Lau LF. Cytotoxicity of TNFalpha is regulated by integrin-mediated matrix signaling. EMBO J 26: 1257-1267, 2007.
8. Cicha I, Yilmaz A, Klein M, Raithel D, Brigstock DR, Daniel WG, Goppelt-Struebe M, and Garlichs CD. Connective tissue growth factor is overexpressed in complicated atherosclerotic plaques and induces mononuclear cell chemotaxis in vitro. Arterioscler Thromb Vasc Biol 25: 1008-1013, 2005.
9. Csányi G1, Yao M, Rodríguez AI, Al Ghouleh I, Sharifi-Sanjani M, Frazziano G, Huang X, Kelley EE, Isenberg JS, and Pagano PJ. Thrombospondin-1 regulates blood flow via CD47 receptor-mediated activation of NADPH oxidase 1. Arterioscler Thromb Vasc Biol 32: 2966-2973, 2012.
10. Cui R, Tieu B, Recinos A, Tilton RG, and Brasier AR. RhoA mediates angiotensin II-induced phospho-Ser536 nuclear factor kappaB/RelA subunit exchange on the interleukin-6 promoter in VSMCs. Circ Res 99: 723-730, 2006.
11. De Winter P, Leoni P, and Abraham D. Connective tissue growth factor: structure-function relationships of a mosaic, multifunctional protein. Growth Factors 26: 80-91, 2008.
12. Dikalov S, Griendling KK, and Harrison DG. Measurement of reactive oxygen species in cardiovascular studies. Hypertension 49: 717-727, 2007.
13. Dreux AC, Lamb DJ, Modjtahedi H, and Ferns GA. The epidermal growth factor receptors and their family of ligands: their putative role in atherogenesis. Atherosclerosis 186: 38-53, 2006.
14. Drummond GR, Selemidis S, Griendling KK, and Sobey CG. Combating oxidative stress in vascular disease: NADPH oxidases as therapeutic targets. Nat Rev Drug Discov 10: 453-471, 2011.
15. Esteban V, Ruperez M, Rodriguez-Vita J, Sanchez-López E, Mezzano S, Plaza JJ, Egido J, and Ruiz-Ortega M. Effect of simultaneous blockade of AT1 and AT2 receptors on the NF-jB pathway and renal inflammatory response. Kidney Int 64: S33-S38, 2003.
16. Esteban V, Lorenzo O, Rupérez M, Suzuki Y, and Ruiz-Ortega M. Angiotensin II, via AT1 and AT2 receptors and NF-kappaB pathway, regulates the inflammatory response in unilateral ureteral obstruction. J Am Soc Nephrol 15: 1514-1529, 2004.
17. Gravning J, Ørn S, Kaasbøll OJ, Martinov VN, Manhenke C, Dickstein K, Edvardsen T, Attramadal H, and Ahmed MS. Myocardial connective tissue growth factor (CCN2/CTGF) attenuates left ventricular remodeling after myocardial infarction. PLoS One 7: e52120, 2012.
18. Hao C, Xie Y, Peng M, Ma L, Zhou Y, Zhang Y, Kang W, Wang J, Bai X, Wang P, and Jia Z. Inhibition of connective tissue growth factor suppresses hepatic stellate cell activation in vitro and prevents liver fibrosis in vivo. Clin Exp Med 14: 141-150, 2014.
19. Hayata N, Fujio Y, Yamamoto Y, Iwakura T, Obana M, Takai M, Mohri T, Nonen S, Maeda M, and Azuma J. Connective tissue growth factor induces cardiac hypertrophy through Akt signaling. Biochem Biophys Res Commun 37: 274-278, 2008.
20. Hehner SP, Hofmann TG, Droge W, and Schmitz ML. The antiinflammatorysesquiterpene lactone Parthenolide inhibits NF-kappa B by targeting the I kappa B kinase complex. J Immunol 163: 5617-5623, 1999.
21. Huang J, Huang H, Wu M, Li J, Xie H, Zhou H, Liao E, and Peng Y. Connective tissue growth factor induces osteogenic differentiation of vascular smooth muscle cells through ERK signaling. Int J Mol Med 32: 423-429, 2013.
22. Juric V, Chen CC, and Lau LF. Fas-mediated apoptosis is regulated by the extracellular matrix protein CCN1 (CYR61) in vitro and in vivo. Mol Cell Biol 29: 3266-3279, 2009.
23. Kagiyama S, Eguchi S, Frank GD, Inagami T, Zhang YC, and Phillips MI. Angiotensin II-induced cardiac hypertrophy and hypertension are attenuated by epidermal growth factor receptor antisense. Circulation 106: 909-912, 2002.
24. Karger A, Fitzner B, Brock p, Sparmann G, Emmrich J, Liebe S, and Jaster R. Molecular insights into connective tissue growth factor action in rat pancreatic stellate cells. Cell Signal 20: 1865-1872, 2008.
25. Kim KH, Chen CC, Monzon RI, and Lau LF. Matricellular protein CCN1 promotes regression of liver fibrosis through induction of cellular senescence in hepatic myofibroblasts. Mol Cell Biol 33: 2078-2090, 2013.
26. Koitabashi N, Arai M, Niwano K, Watanabe A, Endoh M, Suguta M, Yokoyama T, Tada H, Toyama T, Adachi H, Naito S, Oshima S, Nishida T, Kubota S, Takigawa M, and Kurabayashi M. Plasma connective tissue growth factor is a novel potential biomarker of cardiac dysfunction in patients with chronic heart failure. Eur J Heart Fail 10: 373-379, 2008.
27. Kular L, Pakradouni J, Kitabgi P, Laurent M, and Martinerie C. The CCN family: a new class of inflammation modulators? Biochimie 93: 377-388, 2011.
28. Kundi R, Hollenbeck ST, Yamanouchi D, Herman BC, Edlin R, Ryer EJ, Wang C, Tsai S, Liu B, and Kent KC. Arterial gene transfer of the TGF-beta signalling protein Smad3 induces adaptive remodelling following angioplasty: a role for CTGF. Cardiovasc Res 84: 326-335, 2009.
29. Lasségue B, San Martín A, and Griendling KK. Biochemistry, physiology, and pathophysiology of NADPH oxidases in the cardiovascular system. Circ Res 110: 1364-1390, 2012.
30. Laurindo FR, Fernandes DC, and Santos CX. Assessment of superoxide production and NADPH oxidase activity by HPLC analysis of dihydroethidium oxidation products. Methods Enzymol 441: 237-260, 2008.
31. Leask A. CCN2/decorin interactions: a novel approach to combating fibrosis? J Cell Commun Signal 5: 249-250, 2011.
32. Liu BC, Zhang JD, Zhang XL, Wu GQ, and Li MX. Role of connective tissue growth factor (CTGF) module 4 in regulating epithelial mesenchymal transition in HK-2 cells. Clin Chim Acta 373: 144-150, 2006.
33. Liu X, Gai Y, Liu F, Gao W, Zhang Y, Xu M, and Li Z. Trimetazidine inhibits pressure overload-induced cardiac fibrosis through NADPH oxidase-ROS-CTGF pathway. Cardiovasc Res 88: 150-158, 2010.
34. López-Franco O, Hernández-Vargas P, Ortiz-Muñoz G, Sanjuán G, Suzuki Y, Ortega L, Blanco J, Egido J, and Gómez-Guerrero C. Parthenolide modulates the NF-kappaBmediated inflammatory responses in experimental atherosclerosis. Arterioscler Thromb Vasc Bio 26: 1864-1870, 2006.
35. Markiewicz M, Nakerakanti SS, Kapanadze B, Ghatnekar A, and Trojanowska M. Connective tissue growth factor (CTGF/CCN2) mediates angiogenic effect of S1P in human dermal microvascular endothelial cells. Microcirculation 18: 1-11, 2011.
36. Martínez-Revelles S, Avendaño MS, García-Redondo AB, Alvarez Y, Aguado A, Pérez-Girón JV, García-Redondo L, Esteban V, Redondo JM, Alonso MJ, Briones AM, and Salaices M. Reciprocal relationship between reactive oxygen species and cyclooxygenase-2 and vascular dysfunction in hypertension. Antioxid Redox Signal 18: 51-65, 2013.
37. Martín-Ventura JL, Blanco-Colio LM, Gómez-Hernández A, Muñoz-García B, Vega M, Serrano J, Ortega L, Hernández G, Tuñón J, and Egido J. Intensive treatment with atorvastatin reduces inflammation in mononuclear cells and human atherosclerotic lesions in one month. Stroke 36: 1796-1800, 2005.
38. Matrougui K. Diabetes and microvascular pathophysiology: role of epidermal growth factor receptor tyrosine kinase. Diabetes Metab Res Rev 26: 13-16, 2010.
39. Moe IT, Pham TA, Hagelin EM, Ahmed MS, and Attramadal H. CCN2 exerts direct cytoprotective actions in adult cardiac myocytes by activation of the PI3-kinase/Akt/GSK-3b signaling pathway. J Cell Commun Signal 7: 31-47, 2012.
40. Moncada S and Higgs EA. Nitric oxide and the vascular endothelium. Handb Exp Pharmacol (176 Pt 1): 213-254, 2006.
41. Morgan MJ and Liu ZG. Crosstalk of reactive oxygen species and NF-jB signaling. Cell Res 21: 103-115, 2011.
42. Mori T, Kawara S, Shinozaki M, Hayashi N, Kakinuma T, Igarashi A, Takigawa M, Nakanishi T, and Takehara K. Role and interaction of connective tissue growth factor with transforming growth factor-beta in persistent fibrosis: a mouse fibrosis model. J Cell Physiol 181: 153-159, 1999.
43. Münzel T, Gori T, Bruno RM, and Taddei S. Is oxidative stress a therapeutic target in cardiovascular disease? Eur Heart J 31: 2741-2748, 2010.
44. Oemar BS, Werner A, Garnier JM, Do DD, Godoy N, Nauck M, März W, Rupp J, Pech M, and Lüscher TF. Human connective tissue growth factor is expressed in advanced atherosclerotic lesions. Circulation 9: 831-839, 1997.
45. Panek AN, Posch MG, Alenina N, Ghadge SK, Erdmann B, Popova E, Perrot A, Geier C, Dietz R, Morano I, Bader M, and Ozcelik C. Connective tissue growth factor overexpression in cardiomyocytes promotes cardiac hypertrophy and protection against pressure overload. PLoS One 4: e6743, 2009.
46. Park SK, Kim J, Seomun Y, Choi J, Kim DH, Han IO, Lee EH, Chung SK, and Joo CK. Hydrogen peroxide is a novel inducer of connective tissue growth factor. Biochem Biophys Res Commun 284: 966-971, 2001.
47. Perbal B. CCN proteins: multifunctional signaling regulators. Lancet 363: 62-64, 2004.
48. Phanish MK, Winn SK, and Dockrell ME. Connective tissue growth factor-(CTGF, CCN2)-a marker mediator and therapeutic target for renal fibrosis. Nephron Exp Nephrol 114: e83-e92, 2010.
49. Ponticos M, Holmes AM, Shi-wen X, Leoni P, Khan K, Rajkumar VS, Hoyles RK, Bou-Gharios G, Black CM, Denton CP, Abraham DJ, Leask A, and Lindahl GE. Pivotal role of connective tissue growth factor in lung fibrosis: MAPK-dependent transcriptional activation of type I collagen. Arthritis Rheum 60: 2142-2155, 2009.
50. Ponticos M. Connective tissue growth factor (CCN2) in blood vessels. Vascul Pharmacol 58: 189-193, 2013.
51. Rayego-Mateos S, Rodrigues-Díez R, Morgado-Pascual JL, Rodrigues Díez RR, Mas S, Lavoz C, Alique M, Pato J, Keri G, Ortiz A, Egido J, and Ruiz-Ortega M. Connective tissue growth factor is a new ligand of epidermal growth factor receptor. J Mol Cell Biol 5: 323-335, 2013.
52. Rodrigues-Díez R, Rodrigues-Díez RR, Rayego-Mateos S, Suarez-Alvarez B, Lavoz C, Stark Aroeira L, Sánchez-López E, Orejudo M, Alique M, Lopez-Larrea C, Ortiz A, Egido J, and Ruiz-Ortega M. The C-terminal module IV of connective tissue growth factor is a novel immune modulator of the Th17 response. Lab Invest 93: 812-824, 2013.
53. Rodriguez-Vita J, Ruiz-Ortega M, Rupérez M, Esteban V, Sanchez-López E, Plaza JJ, and Egido J. Endothelin-1, via ETA receptor and independently of transforming growth factor-beta, increases the connective tissue growth factor in vascular smooth muscle cells. Circ Res 97: 125-134, 2005.
54. Ruiz-Ortega M and Ortiz A. Angiotensin II and reactive oxygens pecies. Antioxid Redox Signal 7: 1258-1260, 2005.
55. Ruiz-Ortega M, Esteban V, Rupérez M, Sánchez-López E, Rodríguez-Vita J, Carvajal G, and Egido J. Renal and vascular hypertension-induced inflammation: role of angiotensin II. Curr Opin Nephrol Hypertens 15: 159-166, 2006.
56. Ruiz-Ortega M, Rodríguez-Vita J, Sanchez-Lopez E, Carvajal G, and Egido J. TGF-beta signaling in vascular fibrosis. Cardiovasc Res 74: 196-206, 2007.
57. Rupérez M, Lorenzo O, Blanco-Colio LM, Esteban V, Egido J, and Ruiz-Ortega M. Connective tissue growth factor is a mediator of angiotensin II-induced fibrosis. Circulation 108: 1499-1505, 2003.
58. Sánchez-López E, Rodriguez-Vita J, Cartier C, Rupérez M, Esteban V, Carvajal G, Rodrígues-Díez R, Plaza JJ, Egido J, and Ruiz-Ortega M. Inhibitory effect of interleukin-1 on angiotensin II-induced connective tissue growth factor and type IV collagen production in cultured mesangial cells. Am J Physiol Renal Physiol 294: F149-F160, 2008.
59. Sánchez-López E, Rayego S, Rodrigues-Díez R, Rodriguez JS, Rodrigues-Díez R, Rodríguez-Vita J, Carvajal G, Aroeira LS, Selgas R, Mezzano SA, Ortiz A, Egido J, and Ruiz-Ortega M. CTGF promotes inflammatory cell infiltration of the renal interstitium by activating NF-kappaB. J Am Soc Nephrol 20: 1513-1526, 2009.
60. Sanz AB, Sanchez-Niño MD, Ramos AM, Moreno JA, Santamaria B, Ruiz-Ortega M, Egido J, and Ortiz A. NFkappaB in renal inflammation. J Am Soc Nephrol 21: 1254-1262, 2010.
61. Savoia C and Schiffrin EL. Vascular inflammation in hypertension and diabetes: molecular mechanisms and therapeutic interventions. Clin Sci (Lond) 112: 375-384, 2007.
62. Schreier B, Gekle M, and Grossmann C. Role of epidermal growth factor receptor in vascular structure and function. Curr Opin Nephrol Hypertens 23: 113-121, 2014.
63. Seshiah PN, Weber DS, Rocic P, Valppu L, Taniyama Y, and Griendling KK. Angiotensin II stimulation of NAD(P)H oxidase activity: upstream mediators. Circ Res 91: 406-413, 2002.
64. Sirker A, Zhang M, and Shah AM. NADPH oxidases in cardiovascular disease: insights from in vivo models and clinical studies. Basic Res Cardiol 106: 735-747, 2011.
65. Tousoulis D, Kampoli AM, and Stefanadis C. Diabetes mellitus and vascular endothelial dysfunction: current perspectives. Curr Vasc Pharmacol 10: 19-32, 2012.
66. Touyz RM, Briones AM, Sedeek M, Burger D, and Montezano AC. NOX1 isoforms and reactive oxygen species in vascular health. Mol Interv 11: 27-35, 2011.
67. Van Buul JD, Fernandez-Borja M, Anthony EC, and Hordijk PL. Expression and localization of NOX2 and NOX4 in primary human endothelial cells. Antioxid Redox Signal 7: 308-317, 2005.
68. Van der Heiden K, Cuhlmann S, Luong le A, Zakkar M, and Evans PC. Role of nuclear factor kappaB in cardiovascular health and disease. Clin Sci (Lond) 118: 593-605, 2010.
69. Virdis A, Duranti E, and Taddei S. Oxidative stress and vascular damage in hypertension: role of angiotensin II. Int J Hypertens 916310, 2011. DOI: 10.4061/2011/916310.
70. Wang X, McLennan SV, Allen TJ, and Twigg SM. Regulation of pro-inflammatory and pro-fibrotic factors by CCN2/CTGF in H9c2 cardiomyocytes. J Cell Commun Signal 4: 15-23, 2010.
71. Wang R, Xu YJ, Liu XS, Zeng DX, and Xiang M. Knockdown of connective tissue growth factor by plasmidbased short hairpin RNA prevented pulmonary vascular remodeling in cigarette smoke-exposed rats. Arch Biochem Biophys 508: 93-100, 2011.
72. Wu S-H, Lu C, Dong L, and Chen Z-Q. Signal transduction involved in CTGF-induced production of chemokines in mesangial cells. Growth Factors 26: 192-200, 2008.